Please login to the form below

Not currently logged in
Email:
Password:

Stivarga

This page shows the latest Stivarga news and features for those working in and with pharma, biotech and healthcare.

FDA clears Blueprint’s $32k-per-month GI cancer drug

FDA clears Blueprint’s $32k-per-month GI cancer drug

imatinib) and Pfizer’s Sutent (sunitinib), which are also available as generics, and Bayer’s Stivarga (regorafenib) which is still in patent. ... The FDA’s decision has been delayed by three months as Blueprint awaits data from a head-to-head trial

Latest news

More from news
Approximately 12 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

The big issue
Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...

Infographics